What are the yellow liquid and white beads in Tussionex (hydrocodone bitartrate and chlorpheniramine polistirex)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tussionex Formulation Components

The yellow liquid in Tussionex is the suspension vehicle that carries the medication, while the white beads are ion-exchange resin complexes (polistirex) containing the active drugs hydrocodone and chlorpheniramine designed for extended release over 12 hours.

Understanding the Extended-Release Delivery System

  • The white beads are drug-resin complexes where hydrocodone bitartrate and chlorpheniramine are bound to sulfonated styrene-divinylbenzene copolymer (polistirex resin), creating particles that slowly release medication as they pass through the gastrointestinal tract 1.

  • The yellow liquid serves as the suspension medium that keeps these drug-containing beads evenly distributed throughout the formulation, similar to other extended-release bead technologies used in various medications 1.

Clinical Significance of the Formulation

  • This polistirex technology provides sustained drug release over approximately 12 hours, allowing for twice-daily dosing rather than every 4-6 hours dosing required with immediate-release hydrocodone formulations 2, 3.

  • The beads must remain intact to function properly - crushing, chewing, or dissolving the beads destroys the extended-release mechanism and can lead to rapid release of a potentially fatal dose of hydrocodone 4.

Important Safety Considerations

  • Tussionex is contraindicated in patients under 18 years of age due to lack of efficacy data and serious safety concerns including respiratory depression and death in pediatric populations 2.

  • The formulation contains hydrocodone, a Schedule II opioid with significant risks of addiction, abuse, misuse, respiratory depression, and overdose that require careful patient selection and monitoring 4, 5.

  • Hydrocodone is metabolized to hydromorphone, which contributes to both therapeutic effects and toxicity risk, particularly in cases of overdose 3.

References

Guideline

Tussionex Formulation and Delivery Mechanism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Hydrocodone bitartrate for chronic pain.

Drugs of today (Barcelona, Spain : 1998), 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.